Allergan and Kyorin Pharmaceutical Co., Ltd. Sign Exclusive Licensing Agreement to Develop and Market ALPHAGAN-R-/ ALPHAGAN-R- P in Japan.

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--May 26, 2004

Allergan, Inc. (NYSE:AGN) today announced that it has entered into an exclusive licensing agreement with Kyorin Pharmaceutical, Co., Ltd. (Kyorin) in Japan to develop and market the ALPHAGAN(R)/ ALPHAGAN(R) P Franchise (Brimonidine Tartrate solution 0.2 percent and Brimonidine Tartrate Purite solution 0.15 percent) within the ophthalmic specialty area. The ALPHAGAN(R) Franchise represents the third largest selling glaucoma franchise in the world as measured by 2003 revenue, according to IMS Health Inc. In 2003, global sales for the ALPHAGAN(R) Franchise were $287 million.

Under the terms of the licensing agreement, Kyorin will be responsible for the development and commercialization of ALPHAGAN(R)/ ALPHAGAN(R) P in Japan and will incur associated costs. Kyorin will provide Allergan with an up-front payment, as well as development and commercialization milestone payments. In addition, Kyorin will pay Allergan a royalty based on product sales. Allergan and Kyorin will work collaboratively on overall product strategy and management.

Brimonidine tartrate, the active ingredient in ALPHAGAN(R)/ALPHAGAN(R) P is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. It is believed to have a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Due to their favorable safety and efficacy profiles, the ALPHAGAN(R)/ ALPHAGAN(R) P Franchise products have become a preferred choice for the treatment of elevated intraocular pressure in patients with glaucoma and ocular hypertension in numerous markets around the world.

"We are pleased to be entering into this licensing agreement with Kyorin, which is our third such agreement with Kyorin," said David Pyott, Allergan's Chairman of the Board, President and Chief Executive Officer. "Kyorin has proven to be a highly committed partner that is strongly driven to produce a successful outcome. Given the strength of the glaucoma market in Japan, we are confident that Kyorin will maximize the potential of this exceptional technology."

The glaucoma market in Japan is currently estimated to be over $500 million annually. The market has experienced strong growth over the last few years and, given Japan's population demographics, it is expected that the total number of patients will continue to increase.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.

About Kyorin Pharmaceutical, Co., Ltd.

Kyorin Pharmaceutical Co., Ltd., located in Tokyo, Japan, is a fully-integrated, research-oriented pharmaceutical company developing new compounds with a focus in the main therapeutic areas independently, and in collaboration with sophisticated outside research institutes.

Forward-looking Statements

This press release contains "forward-looking statements", including the statements by Mr. Pyott, statements regarding research and development outcomes, efficacy, safety and side-effect profiles, and market and product potential. These statements are based on current expectations of future events. Any other statements in this press release that refer to Allergan's expected, estimated or anticipated future results are also forward-looking statements. All forward-looking statements in this press release reflect Allergan's current analysis of existing trends and information and represent Allergan's judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors affecting Allergan's businesses, including among other things, changing competitive market and regulatory conditions; the timing and uncertainty of the results of both the research and development and regulatory processes; domestic and foreign health care and cost containment reforms; technological advances and patents obtained by competitors; the performance, including the approval, introduction and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the results of any pending litigations, investigations or claims; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and Allergan's ability to obtain and successfully maintain a sufficient supply of products to meet market demand in a timely manner. In addition, matters generally affecting the economy, such as changes in interest and currency exchange rates; international relations; and the state of the economy worldwide, can affect Allergan's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Allergan expressly disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Allergan and its Businesses" in Allergan's 2003 Form 10-K and Allergan's Form 10-Q for the quarter ended March 26, 2004. Copies of Allergan's press releases, and additional information about Allergan is available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 714-246-4636.